A SARS-CoV-2 Vaccination Strategy Focused on Population-Scale Immunity

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) presents challenges for vaccine design due to conserved regions and adaptive mutations.
• Effective vaccines require targeting viral components that are presented by MHC class I and II and are distinct from the human proteome.

Approach:

• Identified conserved viral regions and novel adaptations, including spike protein variations and a furin cleavage site.
• Selected 65 peptide sequences predicted to be B cell epitopes, dissimilar from human proteins.
• Proposed a vaccination strategy for rapid testing in DNA, mRNA, or synthetic peptide vaccine constructs.

Key Points:

• Vaccine targets evolutionarily divergent spike protein regions enhancing ACE2 receptor binding.
• Includes epitopes within a novel furin cleavage site, potentially increasing membrane fusion.
• Designed to engage a robust adaptive immune response in the majority of the human population.

Conclusions:

• The proposed vaccination strategy targets unique SARS-CoV-2 vulnerabilities.
• Aims to provide a safe and effective vaccine candidate for broad population coverage.
• Facilitates rapid preclinical and clinical evaluation across multiple vaccine platforms.